Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases

被引：17

作者：

Blethen, Kathryn E. ^{[1
]}

Arsiwala, Tasneem A. ^{[1
]}

Fladeland, Ross A. ^{[1
]}

Sprowls, Samuel A. ^{[1
]}

Panchal, Dhruvi M. ^{[1
,2
]}

Adkins, Chris E. ^{[4
]}

Kielkowski, Brooke N. ^{[1
]}

Earp, Leland E. ^{[3
]}

Glass, Morgan J. ^{[1
]}

Pritt, Trenton A. ^{[1
]}

Cabuyao, Yssabela M. ^{[1
]}

Aulakh, Sonikpreet ^{[3
]}

Lockman, Paul R. ^{[1
]}

机构：

[1] West Virginia Univ, Sch Pharm, Dept Basic Pharmaceut Sci, 108 Biomed Dr, Morgantown, WV 26506 USA

[2] West Virginia Univ, Benjamin M Statler Coll Engn & Mineral Resources, Dept Chem & Biomed Engn, Morgantown, WV 26506 USA

[3] West Virginia Univ, Sch Med, Dept Canc Cell Biol, Morgantown, WV 26506 USA

[4] South Univ, Sch Pharm, Dept Pharmaceut Sci, Savannah, GA USA

来源：

NEURO-ONCOLOGY ADVANCES | 2021年 / 3卷

关键词：

blood-brain barrier; brain metastases; breast cancer; drug delivery; CELL LUNG-CANCER; RESISTANCE PROTEIN ABCG2; P-GLYCOPROTEIN ABCB1; BREAST-CANCER; INHIBITOR VEMURAFENIB; RADIATION-THERAPY; RANDOMIZED-TRIAL; PERMEABILITY; BEVACIZUMAB; RADIOTHERAPY;

D O I：

10.1093/noajnl/vdab123

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The blood-brain barrier is the selectively permeable vasculature of the brain vital for maintaining homeostasis and neurological function. Low permeability is beneficial in the presence of toxins and pathogens in the blood. However, in the presence of metastatic brain tumors, it is a challenge for drug delivery. Although the blood-tumor barrier is slightly leaky, it still is not permissive enough to allow the accumulation of therapeutic drug concentrations in brain metastases. Herein, we discuss the differences between primary brain tumors and metastatic brain tumors vasculature, effects of therapeutics on the blood-tumor barrier, and characteristics to be manipulated for more effective drug delivery.

引用

页码：V133 / V143

页数：11

共 118 条

[1] Structure and function of the blood-brain barrier [J].

Abbott, N. Joan ;

Patabendige, Adjanie A. K. ;

Dolman, Diana E. M. ;

Yusof, Siti R. ;

Begley, David J. .

NEUROBIOLOGY OF DISEASE, 2010, 37 (01) :13-25

[2] Inflammatory mediators and modulation of blood-brain barrier permeability [J].

Abbott, NJ .

CELLULAR AND MOLECULAR NEUROBIOLOGY, 2000, 20 (02) :131-147

[3] Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer [J].

Adkins, Chris E. ;

Mohammad, Afroz S. ;

Terrell-Hall, Tori B. ;

Dolan, Emma L. ;

Shah, Neal ;

Sechrest, Emily ;

Griffith, Jessica ;

Lockman, Paul R. .

CLINICAL & EXPERIMENTAL METASTASIS, 2016, 33 (04) :373-383

[4] NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer [J].

Adkins, Chris E. ;

Nounou, Mohamed I. ;

Hye, Tanvirul ;

Mohammad, Afroz S. ;

Terrell-Hall, Tori ;

Mohan, Neel K. ;

Eldon, Michael A. ;

Hoch, Ute ;

Lockman, Paul R. .

BMC CANCER, 2015, 15

[5] P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model [J].

Adkins, Chris E. ;

Mittapalli, Rajendar K. ;

Manda, Vamshi K. ;

Nounou, Mohamed I. ;

Mohammad, Afroz S. ;

Terrell, Tori B. ;

Bohn, Kaci A. ;

Yasemin, Celik ;

Grothe, Tiffany R. ;

Lockman, Julie A. ;

Lockman, Paul R. .

FRONTIERS IN PHARMACOLOGY, 2013, 4

[6] The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain [J].

Agarwal, Sagar ;

Sane, Ramola ;

Ohlfest, John R. ;

Elmquist, William F. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 336 (01) :223-233

[7] CAR T cells for brain tumors: Lessons learned and road ahead [J].

Akhavan, David ;

Alizadeh, Darya ;

Wang, Dongrui ;

Weist, Michael R. ;

Shepphird, Jennifer K. ;

Brown, Christine E. .

IMMUNOLOGICAL REVIEWS, 2019, 290 (01) :60-84

[8] Phase II Randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases [J].

Antonadou, D ;

Paraskevaidis, M ;

Sarris, G ;

Coliarakis, N ;

Economou, I ;

Karageorgis, P ;

Throuvalas, N .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3644-3650

[9] Ultrasound-mediated disruption of the blood tumor barrier for improved therapeutic delivery [J].

Arsiwala, T. A. ;

Sprowls, S. A. ;

Blethen, K. E. ;

Adkins, C. E. ;

Saralkar, P. A. ;

Fladeland, R. A. ;

Pentz, W. ;

Gabriele, A. ;

Kielkowski, B. ;

Mehta, R. I. ;

Wang, P. ;

Carpenter, J. S. ;

Ranjan, M. ;

Najib, U. ;

Rezai, A. R. ;

Lockman, P. R. .

NEOPLASIA, 2021, 23 (07) :676-691

[10] Matrix metalloproteinases: Potential therapy to prevent the development of second malignancies after breast radiotherapy [J].

Artacho-Cordon, F. ;

Rios-Arrabal, S. ;

Lara, P. C. ;

Artacho-Cordon, A. ;

Calvente, I. ;

Nunez, M. I. .

SURGICAL ONCOLOGY-OXFORD, 2012, 21 (03) :E143-E151

← 1 2 3 4 5 6 7 8 9 10 →